
    
      This is a multicentre, open-label, controlled Phase 3 study in which adults requiring
      hospital admission and O2 supplementation for management of moderate COVID-19 infection will
      be randomised in 1:1:1 to: Plitidepsin 1.5 mg arm, Plitidepsin 2.5 mg arm and Control arm
    
  